<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35222">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648035</url>
  </required_header>
  <id_info>
    <org_study_id>ML29855</org_study_id>
    <nct_id>NCT02648035</nct_id>
  </id_info>
  <brief_title>EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis</brief_title>
  <official_title>Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Persistence to Tocilizumab SC as Monotherapy or in Combination With cDMARD Treatment in RA Patients in Greece: the EMBRACE-SC Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the percentage of participants treated with
      subcutaneous (SC) Tocilizumab who are still on treatment after 52 weeks and the factors that
      play a major role in continuation of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Still Receiving Subcutaneous Tocilizumab Therapy at 52 Weeks of Observation</measure>
    <time_frame>At 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ) Score</measure>
    <time_frame>At baseline, 24 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain Score in a 100 mm Scale</measure>
    <time_frame>At baseline, 24 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Disease Activity (PtGA) Score in a 100 mm VAS Scale</measure>
    <time_frame>At baseline, 24 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinically Significant Changes in Laboratory Values</measure>
    <time_frame>At baseline, 24 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants on Subcutaneous Tocilizumab Alone Versus Combination Therapy</measure>
    <time_frame>At baseline, 24 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Involved in Subcutaneous Tocilizumab Patient Support Programs (PSPs)</measure>
    <time_frame>At baseline, 24 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs), including Serious Adverse Events (SAEs), Non-Serious Adverse Drug Reactions (nsADRs), Injection Site Reactions (ISRs), and Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Infections Events (IEs), Including Serious and Non-Serious IEs</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with IEs with Laboratory Abnormalities</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Dose Modification of Methotrexate (MTX) or Other Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) Due to AEs or IEs</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Dose Modification of Subcutaneous Tocilizumab Due to AEs or IEs</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants on Glucocorticoids (GCs) with AEs</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score 28 (DAS28)</measure>
    <time_frame>At baseline, 24 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Good/Moderate Response According to the Classification of the European League Against Rheumatism (EULAR)</measure>
    <time_frame>At baseline, 24 and 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Subcutaneous Tocilizumab</arm_group_label>
    <description>Participants receiving treatment for rheumatoid arthritis (RA) with subcutaneous Tocilizumab alone or in combination with conventional disease-modifying antirheumatic drugs (DMARDs) according to approved label.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Subcutaneous Tocilizumab according to approved label.</description>
    <arm_group_label>Subcutaneous Tocilizumab</arm_group_label>
    <other_name>ACTEMRA</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with rheumatoid arthritis for whom the physician has made the decision to
        start subcutaneous Tocilizumab treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Aged &gt;/= 18 years of age with rheumatoid arthritis (RA) for whom the treating physician
        has made the decision to start subcutaneous (SC) Tocilizumab (TCZ) treatment according to
        approved label within 4 weeks prior to enrolment.

        Exclusion Criteria:

          -  Participants who have been receiving Tocilizumab (TCZ) for more than 4 weeks prior to
             enrolment.

          -  Participants who have received TCZ in past treatments.

          -  Participants who have received treatment with any investigational agent within 4
             weeks (or 5 half-lives of investigational agent, whichever is longer) of starting
             treatment TCZ SC.

          -  Participants with a history of autoimmune disease or of any joint inflammatory
             disease other than rheumatoid arthritis (RA).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML29855 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 1, 2016</lastchanged_date>
  <firstreceived_date>January 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
